(IN BRIEF) Roche presented new data at the AD/PD 2025 International Conference demonstrating that trontinemab, in its Phase Ib/IIa Brainshuttle™ AD study, achieves rapid and dose-dependent reductions of amyloid plaques in the brain, with significant biomarker improvements observed in fluid … Read the full press release
Posted in Austria, Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged AD/PD 2025 International Conference, Alzheimer’s disease, amyloid plaques, ARIA-E, biomarkers, Brainshuttle AD study, cognitive impairment, diagnostic solutions, dose-dependent reduction, Elecsys pTau181 plasma test, Levi Garraway, neurogranin, Phase Ib/IIa study, Phase III programme, pTau181, pTau217, Roche, total tau, trontinemab
(PRESS RELEASE) MUNICH, 09-Jan-2019 — /EuropaWire/ — Defects in the geneTREM2 are linked to increased risk of Alzheimer’s disease. The gene is required to activate immune cells called microglia in the brain, which help to eliminate the neurotoxic deposits that are … Read the full press release
Posted in Education, Germany, Healthcare, Science, Technology
Tagged Alzheimer, Alzheimer's, amyloid plaques, Christian Haass, dementia, disease, geneTREM2, microglia, Neurobiology, RESEARCH
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?